April 24th 2024
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Musculoskeletal Manifestations of Pediatric ALL Delayed Diagnosis
January 13th 2017Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.
We review available strategies for screening and risk reduction through chemoprevention or risk-reducing surgery, as well as challenges for management of breast cancer in patients with prior exposure to radiation for Hodgkin lymphoma.
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma
By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.
Breast Cancer After Hodgkin Lymphoma: The Price of Success
December 15th 2016Curative therapy, including chest RT for Hodgkin lymphoma, is associated with a definitively increased risk of breast cancer, most often manifesting approximately 20 years after treatment. These breast cancers tend to be more aggressive, with greater frequency of hormone receptor negativity and potential HER2 positivity.
COUNTERPOINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma
December 15th 2016Management strategies for patients with mantle cell lymphoma continue to demonstrate pendulum-like swings between those appropriate for low-grade lymphoma, and those appropriate for very aggressive lymphoma.
POINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma
December 15th 2016The landscape of mantle cell lymphoma is clearly evolving, due to the availability of new treatment options incorporating novel biologic agents. To optimize therapy, we should build on what has been accomplished over the last 3 decades.
CAR T-Cell Immunotherapy for Aggressive NHL Effective, Feasible in Real-World Setting
December 14th 2016The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma.
Lenalidomide Maintenance Prolongs PFS in Elderly DLBCL
December 13th 2016For the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
Ibrutinib Combination Therapy Safely Treats DLBCL
December 11th 2016Ibrutinib can be safely combined with lenalidomide and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma, according to a new study presented at the American Society of Hematology 58th Annual Meeting and Exposition, held December 3–6.
Understanding the High-Risk Follicular Lymphoma Population
December 8th 2016We are speaking with Sonali Smith, MD, an associate professor of medicine and the director of the lymphoma program at the University of Chicago. At the ASH meeting, Dr. Smith will give a talk called “Emerging Biology Leading to New Therapies in Follicular Lymphoma.”
Brentuximab Improves Responses in CTCL Compared to Standard Care
December 7th 2016Brentuximab vedotin (BV) induces significantly superior clinical outcomes in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL) as compared with physician's choice with methotrexate or bexarotene, according to a new study presented at the American Society of Hematology Annual Meeting & Exposition, held December 3–6, 2016.
DESTINY: CML Patients With Stable Molecular Responses Safely Halved TKI Dose
December 5th 2016Many patients with stable CML may be able to safely decrease their dose of tyrosine kinase inhibitor to half of the standard dose and improve TKI-related side effects, according to the results of the DESTINY trial.
Older AML Patients Survive Longer With New Chemotherapy Delivery Method
December 4th 2016Older patients with AML survive longer after receiving an allogeneic stem cell transplant if they are initially treated with CPX-351 liposome injection instead of the standard “7+3” chemotherapy with cytarabine and daunorubicin.